Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29268948

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2018 Feb 24
First author
Powles T

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2018 Feb 24;391(10122):716-718. doi: 10.1016/S0140-6736(17)33298-1.
    note
    Source null
    related pmid
    29268949
    relationship
    Comment in
  2. citation
    Lancet. 2018 Oct 20;392(10156):1402. doi: 10.1016/S0140-6736(18)32516-9.
    note
    Source null
    related pmid
    30343855
    relationship
    Erratum in

Authors and identifiers

  1. name
    Powles T
    type
    Author
  2. name
    Durán I
    type
    Author
  3. name
    van der Heijden MS
    type
    Author
  4. name
    Loriot Y
    type
    Author
  5. name
    Vogelzang NJ
    type
    Author
  6. name
    De Giorgi U
    type
    Author
  7. name
    Oudard S
    type
    Author
  8. name
    Retz MM
    type
    Author
  9. name
    Castellano D
    type
    Author
  10. name
    Bamias A
    type
    Author
  11. name
    Fléchon A
    type
    Author
  12. name
    Gravis G
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Powles T
    type
    Author
  2. name
    Durán I
    type
    Author
  3. name
    van der Heijden MS
    type
    Author
  4. name
    Loriot Y
    type
    Author
  5. name
    Vogelzang NJ
    type
    Author
  6. name
    De Giorgi U
    type
    Author
  7. name
    Oudard S
    type
    Author
  8. name
    Retz MM
    type
    Author
  9. name
    Castellano D
    type
    Author
  10. name
    Bamias A
    type
    Author
  11. name
    Fléchon A
    type
    Author
  12. name
    Gravis G
    type
    Author
bibliography ids
  1. nci-bib-6cee809aab2ee29b33a8577b
book metadata
content sha256
e1dd0b4e9f08e62701d01a41bf55c126e6c74d8d8329bdf497979186f1f34057
document type
citation
dois
  1. 10.1016/S0140-6736(17)33297-X
electronic publication date
display
2017 Dec 18
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:29268948
immutable id
pubmed:29268948@e1dd0b4e9f08e62701d01a41bf55c126e6c74d8d8329bdf497979186f1f34057
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10122
name
Lancet (London, England)
nlm unique id
2985213R
pages
748-757
volume
391
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2018 Feb 24;391(10122):716-718. doi: 10.1016/S0140-6736(17)33298-1.
    note
    Source null
    related pmid
    29268949
    relationship
    Comment in
  2. citation
    Lancet. 2018 Oct 20;392(10156):1402. doi: 10.1016/S0140-6736(18)32516-9.
    note
    Source null
    related pmid
    30343855
    relationship
    Erratum in
outcomes validated
false
pmid
29268948
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
5d663835c64d0fcb1a4523021387666f59fbc0119e52104c3631b174b1435a5e
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Feb 24
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29268948/
title
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Preserved source evidence · Not medical advice